BALANCE on the Wards: A Pilot RCT
NCT02917551 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 134
Last updated 2020-09-14
Summary
The burden of bloodstream infections is large and increasing over time. Antibiotic overuse continues to drive increased rates of antimicrobial-resistant pathogens across Canada. However, prospective audits have revealed that 30-50% of antibiotic utilization is unnecessary or inappropriate. If shorter duration therapy is as effective as longer duration therapy for these infections, antimicrobial consumption would be decreased. A pilot trial (approved by the Sunnybrook Research Ethics Board), is underway in critically ill patients at 17 Canadian ICUs. Investigators have successfully demonstrated feasibility with respect to protocol adherence and recruitment rates in the ICU. Investigators now aim to conduct a similar pilot RCT among non-ICU patients admitted to hospital wards with bloodstream infections to determine feasibility and protocol adherence of the same trial protocol.
Conditions
- Bacteremia
Interventions
- OTHER
-
7 days of adequate antibiotic treatment
- OTHER
-
14 days of adequate antibiotic treatment
Sponsors & Collaborators
-
Sunnybrook Health Sciences Centre
lead OTHER
Principal Investigators
-
Nick Daneman, MD · Sunnybrook Health Sciences Centre
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-10-10
- Primary Completion
- 2019-11-30
- Completion
- 2020-01-30
Countries
- Canada
Study Locations
More Related Trials
-
BALANCE+ Vanguard Phase
NCT05893147 ·Status: COMPLETED ·Phase: NA
-
Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia
NCT03514446 ·Status: UNKNOWN ·Phase: PHASE4
-
Comparison of Oral Antibiotics For Bone Infections of the Leg and Foot
NCT07266753 ·Status: RECRUITING ·Phase: PHASE4
-
Shortened Antibiotic Treatment of 5 Days in Gram-negative Bacteremia
NCT04291768 ·Status: RECRUITING ·Phase: PHASE4
-
Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by Enterobacteriaceae
NCT02400268 ·Status: COMPLETED ·Phase: PHASE3
-
Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection
NCT02424461 ·Status: COMPLETED ·Phase: PHASE3
-
Short Against Long Antibiotic Therapy for Infected Orthopedic Sites
NCT05499481 ·Status: COMPLETED ·Phase: PHASE3
-
Subcutaneous Suppressive Antibiotic Therapy for Bone and Joint Infections
NCT03403608 ·Status: COMPLETED
-
Prolonged Infusion Cefepime and Nosocomial Infections
NCT02568800 ·Status: UNKNOWN ·Phase: PHASE3
-
Impact of Real-time MIC (Minimum Inhibitory Concentration) Reporting (<6 Hours) on β-lactam Prescription in Cases of Gram-negative Bacilli Bacteremia in ICU Patients in Real-life Settings
NCT07202377 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Antibiotic Outbreak, Risk Factors for Never Event, Prediction of Inappropriate Use
NCT03489330 ·Status: COMPLETED
-
Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia
NCT02972983 ·Status: COMPLETED ·Phase: PHASE4
-
7-day Compared With 10-day Antibiotic Treatment for Febrile Urinary Tract Infections in Children
NCT03221504 ·Status: UNKNOWN ·Phase: NA
-
Selective Reporting of Antibiotic Susceptibility Test Results in Urinary Tract Infections in the Outpatient Setting
NCT03612297 ·Status: UNKNOWN
-
The Use of Prophylactic Antibiotics In the Management of Dog Bites
NCT00185939 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects
NCT02439359 ·Status: COMPLETED ·Phase: PHASE1
-
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
NCT05210387 ·Status: TERMINATED ·Phase: NA
-
Use of Preoperative and Postoperative Antimicrobial Treatment
NCT04707092 ·Status: UNKNOWN ·Phase: PHASE4
-
Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation
NCT01551719 ·Status: WITHDRAWN ·Phase: NA
-
Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion
NCT01198925 ·Status: COMPLETED ·Phase: PHASE4
-
Prophylactic Antibiotics on Urethral Catheter Withdrawal
NCT00126698 ·Status: COMPLETED ·Phase: PHASE4
-
Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia
NCT03108690 ·Status: WITHDRAWN ·Phase: PHASE4
-
Population Pharmacokinetics of Anti-infectives in Hospitalized Patients
NCT02998411 ·Status: RECRUITING
-
Antibiogram and Biofilm Formation of Bacteria Causing Prosthetic Joint Infections Isolated From Assiut University Hospital
NCT05239312 ·Status: UNKNOWN
-
Antibiotic Treatment Duration for Non-Surgically-Treated Diabetic Foot Osteomyelitis
NCT02123628 ·Status: COMPLETED ·Phase: PHASE4